Dallas, TX – June 9, 2020 – Puration, Inc. (OTC PINK: PURA) yesterday published its 11th weekly Coronavirus update. It’s now over a month here in Texas since the economy started a scheduled reopening that still has some graduated steps yet to go. Unfortunately, Texas saw record high new daily cases of Covid-19 last week. However, the hospital utilization rate has remained steady and the death rate is down. The increase in daily cases might be a factor of increased testing efficiencies. PURA management remains optimistic but vigilant in its effort to monitor the potential impact to business operations.
Immediately following the reopening in Texas, PURA moved quickly to reposition its EVERx CBD Sports Water inventory. That effort is complete, and we are now initiating a new production run to avoid any potential EVERx product shortages that could potentially result if another economic shutdown might be forthcoming in reaction to any increase in Covid-19 health risks.
Last week PURA executed a third acquisition for the year to date in conjunction with the campaign launched earlier this year to expand its potential product line of CBD infused beverages, edibles and topicals. The campaign is ongoing with additional potential acquisitions undergoing due diligence at this time.
PURA has a substantial transaction underway involving multiple business entities. The transaction was initially contemplated to rectify the challenges that resulted after PURA spun-off its cannabis cultivation subsidiary to Nouveau (NOUV). The transaction grew to include a timely opportunity with Kali-Extracts’ (KALY) NCM Biotech subsidiary. We expect to publish details regarding the pending transaction later this week.
PURA management continues to monitor the potential impact of the overall Coronavirus crisis to PURA’s operations. To date, PURA’s outlook remains sustainable with even some optimism that certain Coronavirus impacts could be beneficial.
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.